专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20130131039A1 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES 有权
标题翻译：作为JAK KINASES的抑制剂的5,7-取代的咪唑并[1,2-C]吡啶
公开(公告)号：US20130131039A1
公开(公告)日：2013-05-23
申请号：US13640099
申请日：2011-04-11
申请人： Laurence E. Burgess , Mark Laurence Boys , Robert D. Groneberg , Darren M. Harvey , Timothy Kercher , Christopher F. Kraser , Ellen Laird , Eugene Tarlton , Qian Zhao , Lily Huang
发明人： Laurence E. Burgess , Mark Laurence Boys , Robert D. Groneberg , Darren M. Harvey , Timothy Kercher , Christopher F. Kraser , Ellen Laird , Eugene Tarlton , Qian Zhao , Lily Huang
IPC分类号： C07D487/04 , C07D498/04
CPC分类号： C07D487/04 , C07D498/04
摘要： Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
摘要翻译：式I化合物（此处应该插入式）及其其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，X 1和X 2具有本说明书中给出的含义的立体异构体及其药学上可接受的盐和溶剂化物是抑制剂的一种或多种JAK激酶，并且可用于治疗自身免疫性疾病，炎性疾病，移植器官，组织和细胞的排斥，以及血液系统疾病和恶性肿瘤及其并发症。

12. 发明授权

US08962596B2 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases 有权
标题翻译： 5,7-取代 - 咪唑并[1,2-C]嘧啶作为JAK激酶抑制剂
公开(公告)号：US08962596B2
公开(公告)日：2015-02-24
申请号：US13640099
申请日：2011-04-11
申请人： Laurence E. Burgess , Mark Laurence Boys , Robert D. Groneberg , Darren M. Harvey , Timothy Kercher , Christopher F. Kraser , Ellen Laird , Eugene Tarlton , Qian Zhao , Lily Huang
发明人： Laurence E. Burgess , Mark Laurence Boys , Robert D. Groneberg , Darren M. Harvey , Timothy Kercher , Christopher F. Kraser , Ellen Laird , Eugene Tarlton , Qian Zhao , Lily Huang
IPC分类号： C07D487/04 , A61K31/519 , A61P29/00 , A61P35/00 , A61P37/06 , C07D498/04
CPC分类号： C07D487/04 , C07D498/04
摘要： Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
摘要翻译：式I化合物及其其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，X 1和X 2具有本说明书中给出的含义的立体异构体及其药学上可接受的盐和溶剂化物是一种或多种JAK激酶的抑制剂，可用于治疗自身免疫性疾病，炎性疾病，移植器官，组织和细胞排斥，以及血液系统疾病和恶性肿瘤及其并发症。

13. 发明申请

US20060199826A1 Cyclopropane compounds and pharmaceutical use thereof 失效
标题翻译：环丙烷化合物及其药物用途
公开(公告)号：US20060199826A1
公开(公告)日：2006-09-07
申请号：US11011773
申请日：2004-12-15
申请人： Takashi Inaba , Julia Haas , Makoto Shiozaki , Nicole Littmann , Katsutaka Yasue , Steven Andrews , Atushi Sakai , Andrew Fryer , Takafumi Matsuo , Ellen Laird , Akira Suma , Yuichi Shinozaki , Yoshikazu Hori , Hiroto Imai , Tamotsu Negoro
发明人： Takashi Inaba , Julia Haas , Makoto Shiozaki , Nicole Littmann , Katsutaka Yasue , Steven Andrews , Atushi Sakai , Andrew Fryer , Takafumi Matsuo , Ellen Laird , Akira Suma , Yuichi Shinozaki , Yoshikazu Hori , Hiroto Imai , Tamotsu Negoro
IPC分类号： A61K31/496 , A61K31/4436 , A61K31/416 , C07D49/02
CPC分类号： C07C311/29 , C07C311/13 , C07C311/20 , C07C311/22 , C07C311/46 , C07C2601/02 , C07C2601/14 , C07C2603/08 , C07C2603/18 , C07C2603/30 , C07D205/04 , C07D207/48 , C07D209/44 , C07D211/58 , C07D211/96 , C07D213/18 , C07D213/65 , C07D213/71 , C07D213/74 , C07D213/81 , C07D213/82 , C07D217/08 , C07D231/12 , C07D233/64 , C07D237/12 , C07D239/22 , C07D243/08 , C07D257/04 , C07D261/08 , C07D271/06 , C07D271/107 , C07D277/26 , C07D277/36 , C07D277/82 , C07D295/26 , C07D307/79 , C07D307/91 , C07D333/18 , C07D333/34 , C07D333/36 , C07D333/38 , C07D333/62 , C07D401/04 , C07D409/04 , C07D409/12 , C07D413/04 , C07D417/04 , C07D417/12 , C07D471/04 , C07D487/04 , C07D513/04
摘要： The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X1 is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1-(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供具有聚集蛋白聚糖蛋白聚糖酶抑制活性和MMP-13抑制活性的化合物，可用作骨关节炎，类风湿性关节炎等的治疗剂，更具体而言，可以使用式（1）的环丙烷化合物：其中R 1 是 - （CH 2）2 -X-（CH 2）n - SUP> 1等，其中m和n相同或不同，并且各自为0至6，X 1是单键等，而A 1， SUP>是取代的C 3-14烃环基等; R 2和R 3相同或不同，并且各自为氢原子， - （CH 2）2 N 其中p和q为 - （CH 2）2 - - - - CH 2 - 相同或不同，并且各自为0至6，X 1为单键等，而A 2为任选取代的C 3-14烷基，烃环等; R 4是-CO 2 R 9等，其中R 9是氢原子等。 ; 和R 20和R 21相同或不同，各自为氢原子， - （CH 2 CH 2）m 12 其中m12和m12（其中m12和m12）相同或不同，各自为0至6，X 12为单键等，R 30为氢原子等; 或其前药或其药学上可接受的盐。

14. 发明授权

US06646737B2 Submicron dimensional calibration standards and methods of manufacture and use 有权
标题翻译：亚微米尺寸校准标准和制造和使用方法
公开(公告)号：US06646737B2
公开(公告)日：2003-11-11
申请号：US09961629
申请日：2001-09-24
申请人： Marco Tortonese , Ian Smith , Ellen Laird , Bradley W. Scheer
发明人： Marco Tortonese , Ian Smith , Ellen Laird , Bradley W. Scheer
IPC分类号： G01R3126
CPC分类号： G01Q40/02 , H01J2237/30444
摘要： A calibration standard which may be used to calibrate lateral dimensional measurement systems is provided. The calibration standard may include a first substrate spaced from a second substrate. In addition, the calibration standard may include at least one layer disposed between the first and second substrates. The layer may have a traceably measured thickness. For example, a thickness of the layer may be traceably measured using any measurement technique in which a measurement system may be calibrated with a standard reference material traceable to a national testing authority. The calibration standard may be cross-sectioned in a direction substantially perpendicular to an upper surface of the first substrate. The cross-sectioned portion of the calibration standard may form a viewing surface of the calibration standard. In this manner, a lateral dimensional artifact of the calibration standard may include the traceably measured thickness of at least the one layer.
摘要翻译：提供了可用于校准横向尺寸测量系统的校准标准。校准标准可以包括与第二衬底间隔开的第一衬底。此外，校准标准可以包括设置在第一和第二基板之间的至少一层。该层可以具有可追溯测量的厚度。例如，可以使用任何测量技术来可追溯地测量该层的厚度，其中可以使用可追溯到国家检测机构的标准参考材料校准测量系统。校准标准可以在基本上垂直于第一衬底的上表面的方向上横截面。校准标准的横截面部分可以形成校准标准的观察表面。以这种方式，校准标准的横向尺寸伪影可以包括至少一层的可追溯测量的厚度。

15. 发明授权

US07301638B1 Dimensional calibration standards 有权
标题翻译：尺寸校准标准
公开(公告)号：US07301638B1
公开(公告)日：2007-11-27
申请号：US10770151
申请日：2004-01-31
申请人： Marco Tortonese , Jerry Prochazka , Ellen Laird , Pat Brady , Rene M. Blanquies
发明人： Marco Tortonese , Jerry Prochazka , Ellen Laird , Pat Brady , Rene M. Blanquies
IPC分类号： G01N21/84
CPC分类号： G01B11/0616 , G01B21/042
摘要： A calibration standard, for calibrating lateral or angular dimensional measurement systems, is provided. The standard may include a first substrate spaced from a second substrate. The standard may be cross-sectioned in a direction substantially perpendicular or substantially non-perpendicular to an upper surface of the first substrate. The cross-sectioned portion of the standard may form a viewing surface of the calibration standard. The standard may include at least one layer disposed between the first and second substrates. The layer, or a feature etched into the first or second substrate or a feature etched into the layer may have a traceably measured thickness or may be oriented at a traceably measured angle with respect to the viewing surface. A thickness or angle of the layer or other feature may be traceably measured using any technique for calibrating a measurement system with a standard reference material traceable to a national testing authority.
摘要翻译：提供了用于校准横向或角度尺寸测量系统的校准标准。标准可以包括与第二衬底间隔开的第一衬底。标准可以在基本上垂直于或基本上不垂直于第一基板的上表面的方向上横截面。标准的横截面部分可以形成校准标准的观察表面。标准可以包括设置在第一和第二基板之间的至少一层。蚀刻到第一或第二基底中的层或特征或蚀刻到该层中的特征可以具有可追溯测量的厚度，或者可相对于观察表面以可追溯测量的角度定向。层或其他特征的厚度或角度可以使用用于校准具有可追溯到国家检测机构的标准参考材料的测量系统的任何技术来追溯地测量。

16. 发明申请

US20120157452A1 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE 审中-公开
标题翻译：用于抑制RAF激酶的1H-吡唑并[3,4-B]吡啶化合物
公开(公告)号：US20120157452A1
公开(公告)日：2012-06-21
申请号：US13393076
申请日：2010-08-27
申请人： Stefan Gradl , Ellen Laird , David Moreno , Li Ren , Steven Mark Wenglowsky
发明人： Stefan Gradl , Ellen Laird , David Moreno , Li Ren , Steven Mark Wenglowsky
IPC分类号： A61K31/437 , A61P35/00 , A61P13/12 , A61K31/4709 , A61K31/506 , A61K31/497 , A61K31/5377 , C07D471/04 , A61K31/444
CPC分类号： C07D471/04
摘要： Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [FORMULA I]
摘要翻译：式I化合物可用于抑制Raf激酶。公开了使用式I化合物和其立体异构体，互变异构体和其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。 [公式I]

17. 发明授权

US08044083B2 Kinase inhibitors and methods of use thereof 有权
标题翻译：激酶抑制剂及其使用方法
公开(公告)号：US08044083B2
公开(公告)日：2011-10-25
申请号：US12161412
申请日：2007-01-26
申请人： Robert Groneberg , Laurence E. Burgess , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
发明人： Robert Groneberg , Laurence E. Burgess , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
IPC分类号： A61K31/416 , C07D231/56
CPC分类号： C07D231/40 , C07D231/56
摘要： The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases.
摘要翻译：式（I）化合物及其药学上可接受的盐和前药可用于治疗和预防由激酶介导的各种疾病。

18. 发明授权

US08039639B2 Kinase inhibitors and methods of use thereof 有权
标题翻译：激酶抑制剂及其使用方法
公开(公告)号：US08039639B2
公开(公告)日：2011-10-18
申请号：US13020578
申请日：2011-02-03
申请人： Robert Groneberg , Laurence E. Burges , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
发明人： Robert Groneberg , Laurence E. Burges , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
IPC分类号： C07D231/56
CPC分类号： C07D231/40 , C07D231/56
摘要： A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.
摘要翻译：式II化合物及其盐可用于制备式I化合物及其药学上可接受的盐和前药。

19. 发明申请

US20110124878A1 KINASE INHIBITORS AND METHODS OF USE THEREOF 有权
标题翻译：激酶抑制剂及其使用方法
公开(公告)号：US20110124878A1
公开(公告)日：2011-05-26
申请号：US13020578
申请日：2011-02-03
申请人： Robert Groneberg , Laurence E. Burges , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
发明人： Robert Groneberg , Laurence E. Burges , Darren Harvey , Ellen Laird , Mark C. Munson , James P. Rizzi , Martha Rodriguez , Charles Todd Eary , Daniel John Watson
IPC分类号： C07D231/56
CPC分类号： C07D231/40 , C07D231/56
摘要： A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.
摘要翻译：式II化合物及其盐可用于制备式I化合物及其药学上可接受的盐和前药。

20. 发明授权

US07453571B1 Dimensional calibration standards 有权
标题翻译：尺寸校准标准
公开(公告)号：US07453571B1
公开(公告)日：2008-11-18
申请号：US11945871
申请日：2007-11-27
申请人： Marco Tortonese , Jerry Prochazka , Ellen Laird , Pat Brady , René M. Blanquies
发明人： Marco Tortonese , Jerry Prochazka , Ellen Laird , Pat Brady , René M. Blanquies
IPC分类号： G01N21/84
CPC分类号： G01B11/0616 , G01B21/042
摘要： A calibration standard, for calibrating lateral or angular dimensional measurement systems, is provided. The standard may include a first substrate spaced from a second substrate. The standard may be cross-sectioned in a direction substantially perpendicular or substantially non-perpendicular to an upper surface of the first substrate. The cross-sectioned portion of the standard may form a viewing surface of the calibration standard. The standard may include at least one layer disposed between the first and second substrates. The layer, or a feature etched into the first or second substrate or a feature etched into the layer may have a traceably measured thickness or may be oriented at a traceably measured angle with respect to the viewing surface. A thickness or angle of the layer or other feature may be traceably measured using any technique for calibrating a measurement system with a standard reference material traceable to a national testing authority.
摘要翻译：提供了用于校准横向或角度尺寸测量系统的校准标准。标准可以包括与第二衬底间隔开的第一衬底。标准可以在基本上垂直于或基本上不垂直于第一基板的上表面的方向上横截面。标准的横截面部分可以形成校准标准的观察表面。标准可以包括设置在第一和第二基板之间的至少一层。蚀刻到第一或第二基底中的层或特征或蚀刻到该层中的特征可以具有可追溯测量的厚度，或者可相对于观察表面以可追溯测量的角度定向。层或其他特征的厚度或角度可以使用用于校准具有可追溯到国家检测机构的标准参考材料的测量系统的任何技术来追溯地测量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式